SABS – sab biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Wall Stree
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: BIOTECHNOLOGY VALUE FUND L P
Form SCHEDULE 13G SAB Biotherapeutics, Filed by: Woodline Partners LP
Form 10-Q SAB Biotherapeutics, For: Sep 30
Form 424B3 SAB Biotherapeutics,
Form SCHEDULE 13G SAB Biotherapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.